药物联合认知行为治疗复发性抑郁障碍的效果

Effect of drugs combined with cognitive behavior therapy for recurrent depressive disorder

目的观察对复发性抑郁障碍患者实施药物联合认知行为治疗的效果。方法选取2019年6月—2020年9月惠州市第二人民医院及惠州市复员退伍军人医院收治的100例复发性抑郁障碍患者,将其按照入院时间予以分组,每组各50例。对照组实施药物治疗,研究组实施药物联合认知行为治疗,对比分析两组治疗前后汉密尔顿抑郁量表(HAMD)、抑郁自评量表(SDS)、健康调查简表(SF-36)评分及不良反应发生情况。结果治疗前两组的HAMD评分比较,差异无统计学意义(P>0.05);治疗4、8周时两组的HAMD评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗前两组的SDS评分比较,差异无统计学意义(P>0.05);治疗4、8周时两组的SDS评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗前两组的SF-36评分比较,差异无统计学意义(P>0.05);治疗4、8周时两组的SF-36评分均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05)。两组的头痛、便秘、恶心、心动过速、口干、困倦、食欲增加、体重增加等不良反应总发生率比较,差异无统计学意义(P>0.05)。结论对于复发性抑郁障碍患者,药物联合认知行为治疗可有效改善临床症状,而且具备较高的安全性,临床价值显著。

Objective To observe the effect of drugs combined with cognitive behavior therapy for recurrent depressive disorder.Methods From June 2019 to September 2020,100 patients with recurrent depressive disorder in Huizhou Second People′s Hospital and Huizhou Demobilized Veterans Hospital were selected,and they were divided into two groups according to the admission time,50 cases in each group.The control group was given drug treatment,and the study group was given drug combined with cognitive behavior therapy.The Hamilton depression scale(HAMD),self-rating depression scale(SDS)and the MOS item short from health survey(SF-36)scores before and after treatment and incidence of adverse reactions were compared and analyzed between the two groups.Results There was no significant difference in HAMD score between the two groups before treatment(P>0.05).At 4 and 8 weeks of treatment,the HAMD scores of the two groups were lower than those before treatment,and those in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in SDS score between the two groups before treatment(P>0.05).At 4 and 8 weeks of treatment,the SDS scores of the two groups were lower than those before treatment,and those in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in SF-36 score between the two groups before treatment(P>0.05).At 4 and 8 weeks of treatment,the SF-36 scores of the two groups were higher than those before treatment,and those in the study group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions such as headache,constipation,nausea,tachycardia,dry mouth,drowsiness,increase in appetite,and weight gain between the two groups(P>0.05).Conclusion For patients with recurrent depressive disorder,drugs combined with cognitive behavioral therapy can effectively improve clinical symptoms,with high security,and the clinical value is remarkable.